Etizolam in the treatment of generalized anxiety disorder: A controlled clinical trial

A. Bertolino, E. Mastucci, V. Porro, L. Corfiati, M. Palermo, U. Ecari, G. Ceccarelli

Research output: Contribution to journalArticlepeer-review

Abstract

A total of 45 patients with generalized anxiety disorders were treated twice daily for 2 weeks, on a double-blind basis, with 0.5 mg etizolam, 0.5 mg alprazolam or 3 mg bromazepam, and symptoms were assessed using Hamilton's rating scale for anxiety and Hamilton's rating scale for depression. Patients then received the same drug for a further 2 weeks, the drugs being given three times daily if a poor response was observed during the first 2 weeks. All drugs displayed equivalent anxiolytic activity after 2 weeks, but etizolam displayed a progressive increase in anxiolytic activity over 4 weeks of treatment. Etizolam also possessed a more marked antidepressant effect than did alprazolam or bromazepam. There were no differences in the tolerability of the three drugs.

Original languageEnglish
Pages (from-to)455-460
Number of pages6
JournalJournal of International Medical Research
Volume17
Issue number5
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Etizolam in the treatment of generalized anxiety disorder: A controlled clinical trial'. Together they form a unique fingerprint.

Cite this